Literature DB >> 17166884

Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.

Katri Pylkäs1, Johanna Tommiska, Kirsi Syrjäkoski, Juha Kere, Magtouf Gatei, Nicola Waddell, Minna Allinen, Sanna-Maria Karppinen, Katrin Rapakko, Helena Kääriäinen, Kristiina Aittomäki, Carl Blomqvist, Aki Mustonen, Kaija Holli, Kum Kum Khanna, Olli-Pekka Kallioniemi, Heli Nevanlinna, Robert Winqvist.   

Abstract

Biallelic mutations in the ataxia-telangiectasia mutated (ATM) gene result in ataxia-telangiectasia (A-T). Studies on A-T families have shown that obligate female carriers have increased risk of developing breast cancer. Here we have evaluated the role of known Finnish ATM germ line mutations as possible breast cancer predisposing alleles outside A-T families by analyzing their prevalence in large cohorts of familial and unselected breast cancer cases. Of seven different alterations, two were observed in the studied breast cancer material. ATM 6903insA (causing protein truncation) was seen in 3/541 familial and 5/1124 unselected cases, but not among healthy population controls (0/1107). 7570G>C (Ala2524Pro) occurred in 1/541 familial and 2/1124 unselected cases compared with 1/1107 in controls. Additionally, 8734A>G (Arg2912Gly) associated previously with breast cancer susceptibility and suggested to be causative also for A-T was detected in 2/541 of familial cases, but not in unselected cases (0/1124) or controls (0/1107). In total, heterozygous ATM mutation carriers were observed in 6/541 familial [P = 0.006, odds ratio (OR) 12.4, 95% confidence interval (CI) 1.5-103.3) and 7/1124 unselected cases (P = 0.07, OR 6.9, 95% CI 0.9-56.4), compared with 1/1107 in controls, suggesting an apparent yet overall limited contribution to predisposition to cancer. The current results also provided evidence for founder effects in the geographical distribution of these mutations. Interestingly, results from functional analysis of the breast cancer-associated ATM mutations indicated that cancer susceptibility is not restricted to mutations with dominant-negative effect on kinase activity, displayed only by 7570G>C, whereas 8734A>G showed only a partial defect in the phosphorylation of ATM substrates, and 6903insA seemed to be a null allele.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166884     DOI: 10.1093/carcin/bgl237

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

1.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

Authors:  Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2009-09-24       Impact factor: 11.025

2.  Molecular genetics of breast and ovarian cancer: recent advances and clinical implications.

Authors:  N Bogdanova; T Dörk
Journal:  Balkan J Med Genet       Date:  2012-12       Impact factor: 0.519

3.  Assessment of targeted and non-targeted responses in cells deficient in ATM function following exposure to low and high dose X-rays.

Authors:  Anne Kiuru; Meerit Kämäräinen; Sirpa Heinävaara; Katri Pylkäs; Kim Chapman; Armi Koivistoinen; Teuvo Parviainen; Robert Winqvist; Munira Kadhim; Virpi Launonen; Carita Lindholm
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

4.  Hereditary breast cancer: ever more pieces to the polygenic puzzle.

Authors:  Natalia Bogdanova; Sonja Helbig; Thilo Dörk
Journal:  Hered Cancer Clin Pract       Date:  2013-09-11       Impact factor: 2.857

5.  Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.

Authors:  Tuomo Mantere; Anna Tervasmäki; Anna Nurmi; Katrin Rapakko; Saila Kauppila; Jiangbo Tang; Johanna Schleutker; Anne Kallioniemi; Jaana M Hartikainen; Arto Mannermaa; Pentti Nieminen; Riitta Hanhisalo; Sini Lehto; Maija Suvanto; Mervi Grip; Arja Jukkola-Vuorinen; Maria Tengström; Päivi Auvinen; Anders Kvist; Åke Borg; Carl Blomqvist; Kristiina Aittomäki; Roger A Greenberg; Robert Winqvist; Heli Nevanlinna; Katri Pylkäs
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

6.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

7.  Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.

Authors:  Elena Bueno-Martínez; Lara Sanoguera-Miralles; Alberto Valenzuela-Palomo; Ada Esteban-Sánchez; Víctor Lorca; Inés Llinares-Burguet; Jamie Allen; Alicia García-Álvarez; Pedro Pérez-Segura; Mercedes Durán; Douglas F Easton; Peter Devilee; Maaike Pg Vreeswijk; Miguel de la Hoya; Eladio A Velasco-Sampedro
Journal:  J Pathol       Date:  2022-07-15       Impact factor: 9.883

8.  Variants in the ATM gene and breast cancer susceptibility.

Authors:  Roger L Milne
Journal:  Genome Med       Date:  2009-01-22       Impact factor: 11.117

9.  Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.

Authors:  Katri Pylkäs; Hannele Erkko; Jenni Nikkilä; Szilvia Sólyom; Robert Winqvist
Journal:  BMC Cancer       Date:  2008-05-26       Impact factor: 4.430

10.  Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Geir Åsmund Myge Hansen; Siri Skarsfjord; Christoffer Jonsrud; Monica Ingebrigtsen; Nina Strømsvik; Marijke Van Ghelue
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.